Bioequivalence for topical dermatological drug products will be discussed by FDA's Pharmaceutical Science Advisory Committee March 12. The agency had issued a draft guidance on dermatopharmacokinetics, but is now considering alternatives (1"The Pink Sheet" Dec. 17, 2001, p. 40). Process Analytical Technologies Subcommittee's final report will also be presented, and the new Manufacturing, Biopharmaceutics and Microbiology subcommittees will be discussed...
You may also be interested in...
FDA is considering evaluating alternatives to dermatopharmacokinetics for determining bioequivalence of topical dermatological products
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.